Polycythemia Vera

"Polycythemia Vera" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A myeloproliferative disorder of unknown etiology, characterized by abnormal proliferation of all hematopoietic bone marrow elements and an absolute increase in red cell mass and total blood volume, associated frequently with splenomegaly, leukocytosis, and thrombocythemia. Hematopoiesis is also reactive in extramedullary sites (liver and spleen). In time myelofibrosis occurs.

Descriptor ID	D011087
MeSH Number(s)	C04.588.448.200.500 C15.378.190.250.500 C15.378.190.636.753 C15.378.400.200.500
Concept/Terms	Polycythemia Vera Polycythemia Vera Primary Polycythemia Polycythemia, Primary Polycythemias, Primary Primary Polycythemias Polycythemia Rubra Vera Polycythemia Rubra Veras Vera, Polycythemia Rubra Veras, Polycythemia Rubra Polycythemia Ruba Vera Polycythemia Ruba Veras Ruba Vera, Polycythemia Ruba Veras, Polycythemia Vera, Polycythemia Ruba Veras, Polycythemia Ruba Osler-Vaquez Disease Disease, Osler-Vaquez Osler Vaquez Disease Erythremia Erythremias

Below are MeSH descriptors whose meaning is more general than "Polycythemia Vera".

Diseases [C]
Neoplasms [C04]
Neoplasms by Site [C04.588]
Hematologic Neoplasms [C04.588.448]
Bone Marrow Neoplasms [C04.588.448.200]
Polycythemia Vera [C04.588.448.200.500]
Hemic and Lymphatic Diseases [C15]
Hematologic Diseases [C15.378]
Bone Marrow Diseases [C15.378.190]
Bone Marrow Neoplasms [C15.378.190.250]
Polycythemia Vera [C15.378.190.250.500]
Myeloproliferative Disorders [C15.378.190.636]
Polycythemia Vera [C15.378.190.636.753]
Hematologic Neoplasms [C15.378.400]
Bone Marrow Neoplasms [C15.378.400.200]
Polycythemia Vera [C15.378.400.200.500]

Below are MeSH descriptors whose meaning is related to "Polycythemia Vera".

Below are MeSH descriptors whose meaning is more specific than "Polycythemia Vera".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Polycythemia Vera" by people in this website by year, and whether "Polycythemia Vera" was a major or minor topic of these publications.

Bar chart showing 102 publications over 20 distinct years, with a maximum of 17 publications in 2017

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1999	0	1	1
2002	0	1	1
2003	0	1	1
2004	1	0	1
2005	0	2	2
2006	4	0	4
2007	11	3	14
2008	2	1	3
2009	5	0	5
2010	2	0	2
2011	1	2	3
2012	1	0	1
2013	5	1	6
2014	7	0	7
2015	13	2	15
2016	9	1	10
2017	14	3	17
2018	4	0	4
2019	2	2	4
2020	1	0	1

Below are the most recent publications written about "Polycythemia Vera" by people in Profiles.

Kiladjian JJ, Zachee P, Hino M, Pane F, Masszi T, Harrison CN, Mesa R, Miller CB, Passamonti F, Durrant S, Griesshammer M, Kirito K, Besses C, Moiraghi B, Rumi E, Rosti V, Blau IW, Francillard N, Dong T, Wroclawska M, Vannucchi AM, Verstovsek S. Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study. Lancet Haematol. 2020 Mar; 7(3):e226-e237.

View in: PubMed
Santos FPS, Getta B, Masarova L, Famulare C, Schulman J, Datoguia TS, Puga RD, Alves Paiva RM, Arcila ME, Hamerschlak N, Kantarjian HM, Levine RL, Campregher PV, Rampal RK, Verstovsek S. Prognostic impact of RAS-pathway mutations in patients with myelofibrosis. Leukemia. 2020 03; 34(3):799-810.

View in: PubMed
Masarova L, Verstovsek S. The evolving understanding of prognosis in post-essential thrombocythemia myelofibrosis and post-polycythemia vera myelofibrosis vs primary myelofibrosis. Clin Adv Hematol Oncol. 2019 May; 17(5):299-307.

View in: PubMed
Hidalgo-Lopez JE, Kanagal-Shamanna R, Reyes S, Zhao C, Medeiros LJ, Bueso-Ramos CE. Ring sideroblasts in chronic phase of polycythemia vera identifies a subset of patients with an increased risk of progression to blast phase. Ann Diagn Pathol. 2019 Jun; 40:45-48.

View in: PubMed
Bose P, Masarova L, Verstovsek S. Novel treatment strategies for myeloproliferative neoplasms. Rinsho Ketsueki. 2019; 60(9):1176-1185.

View in: PubMed
Tashi T, Swierczek S, Kim SJ, Salama ME, Song J, Heikal N, King KY, Hickman K, Litton S, Prchal JT. Pegylated interferon Alfa-2a and hydroxyurea in polycythemia vera and essential thrombocythemia: differential cellular and molecular responses. Leukemia. 2018 08; 32(8):1830-1833.

View in: PubMed
Kiladjian JJ, Guglielmelli P, Griesshammer M, Saydam G, Masszi T, Durrant S, Passamonti F, Jones M, Zhen H, Li J, Gadbaw B, Perez Ronco J, Khan M, Verstovsek S. Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies. Ann Hematol. 2018 Apr; 97(4):617-627.

View in: PubMed
Masarova L, Alhuraiji A, Bose P, Daver N, Pemmaraju N, Cortes J, Pierce S, Kantarjian H, Verstovsek S. Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis. Eur J Haematol. 2018 Mar; 100(3):257-263.

View in: PubMed
Bose P, Gotlib J, Harrison CN, Verstovsek S. SOHO State-of-the-Art Update and Next Questions: MPN. Clin Lymphoma Myeloma Leuk. 2018 01; 18(1):1-12.

View in: PubMed
Hidalgo López JE, Carballo-Zarate A, Verstovsek S, Wang SA, Hu S, Li S, Xu J, Zuo W, Tang Z, Yin CC, Medeiros LJ, Bueso-Ramos CE, Tang G. Bone marrow findings in blast phase of polycythemia vera. Ann Hematol. 2018 Mar; 97(3):425-434.

View in: PubMed

People

Explore

Similar Concepts

Top Journals